The rationale of a peptide-conjugate vaccine against measles

Mike M. Pütz, Claude P. Muller*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


The live-attenuated measles vaccine is poorly immunogenic in infants because of immune suppressive maternal antibodies and immaturity of the infant's immune system. Selected peptides corresponding to sequential, subdominant B cell epitopes of measles virus (MV) glycoproteins have been shown to induce neutralizing and protective antibodies even in the presence of whole virus antibodies. Similar to polysaccharide-conjugate vaccines, which are highly effective in infants a peptide-conjugate vaccine against measles is proposed. Such a vaccine induces carrier-specific T cells, avoiding measles-specific Th2 cells associated with the risk of atypical measles. This article discusses the rationale of such a strategy and its future potential.

Original languageEnglish
Pages (from-to)663-666
Number of pages4
Issue number7-8
Publication statusPublished - 30 Jan 2003
Externally publishedYes


  • Atypical measles
  • Conjugate vaccine
  • Infant immunization
  • Measles virus (MV)
  • Synthetic peptides


Dive into the research topics of 'The rationale of a peptide-conjugate vaccine against measles'. Together they form a unique fingerprint.

Cite this